Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth

Fayi Wu, Stephanie O. Peacock, Shuyun Rao, Sandra Lemmon, Kerry L Burnstein

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.

Original languageEnglish
Pages (from-to)5463-5474
Number of pages12
JournalJournal of Biological Chemistry
Volume288
Issue number8
DOIs
StatePublished - Feb 22 2013

Fingerprint

rho GTP-Binding Proteins
Androgen Receptors
Prostatic Neoplasms
Growth
Guanine Nucleotide Exchange Factors
Rho Guanine Nucleotide Exchange Factors
Cell proliferation
Chemical activation
Cell Proliferation
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth. / Wu, Fayi; Peacock, Stephanie O.; Rao, Shuyun; Lemmon, Sandra; Burnstein, Kerry L.

In: Journal of Biological Chemistry, Vol. 288, No. 8, 22.02.2013, p. 5463-5474.

Research output: Contribution to journalArticle

@article{f86d6cc5b36a444d99d27b9e60cb69a1,
title = "Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth",
abstract = "Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.",
author = "Fayi Wu and Peacock, {Stephanie O.} and Shuyun Rao and Sandra Lemmon and Burnstein, {Kerry L}",
year = "2013",
month = "2",
day = "22",
doi = "10.1074/jbc.M112.390963",
language = "English",
volume = "288",
pages = "5463--5474",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "8",

}

TY - JOUR

T1 - Novel interaction between the co-chaperone cdc37 and rho gtpase exchange factor vav3 promotes androgen receptor activity and prostate cancer growth

AU - Wu, Fayi

AU - Peacock, Stephanie O.

AU - Rao, Shuyun

AU - Lemmon, Sandra

AU - Burnstein, Kerry L

PY - 2013/2/22

Y1 - 2013/2/22

N2 - Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.

AB - Background: The Rho GTPase guanine nucleotide exchange factor, Vav3, is overexpressed in human prostate cancer and enhances androgen receptor transcriptional activity. Results: Cdc37 is a novel Vav3 binding partner that enhances androgen receptor co-activation by Vav3 and increases prostate cancer cell proliferation. Conclusion: Vav3-Cdc37 interaction is required for maximal androgen receptor function and prostate cancer growth. Significance: Vav3-Cdc37 interaction is a potential therapeutic target for prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84874324273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874324273&partnerID=8YFLogxK

U2 - 10.1074/jbc.M112.390963

DO - 10.1074/jbc.M112.390963

M3 - Article

C2 - 23281476

AN - SCOPUS:84874324273

VL - 288

SP - 5463

EP - 5474

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 8

ER -